CereneSan Francisco, Calif. — (November 6, 2025) — Channel Medsystems, a commercial-stage women’s health company, today announced that more than 5,000 women have now been treated with the Cerene® Cryotherapy Device, underscoring the growing clinical and commercial adoption of the company’s innovative solution for heavy menstrual bleeding (HMB) and dysmenorrhea.
Cerene is an FDA-approved endometrial cryoablation device designed to be used in a gynecologist’s office without general anesthesia or operating-room resources. The milestone reflects expanding adoption across hospitals, ambulatory surgery centers, and private OB/GYN practices nationwide.
“Reaching 5,000 cases demonstrates how quickly Cerene has become an integral part of the modern gynecologist’s toolkit,” said Paul Russo Vice President of Sales at Channel Medsystems. “Physicians appreciate its ease of use, patients appreciate the comfort and safety, and health systems appreciate the efficiency and economics of an in-office treatment that delivers long-term relief.”
The 5,000-procedure milestone follows a period of accelerated momentum for Channel Medsystems, which continues to expand its national footprint through commercial team growth, strategic partnerships, physician education programs, and growing payer coverage. The company’s focus on advancing cryotherapy as a new standard of care in heavy menstrual bleeding supports its mission to empower every woman to take control of her health journey.
“Each Cerene procedure represents a woman choosing to address heavy bleeding and dysmenorrhea in a way that fits her life,” said Nelson Whistance, President and Chief Executive Officer of Channel Medsystems. “This milestone validates both the clinical impact of cryotherapy and the dedication of our growing network of providers who are redefining care for women everywhere.”
About Channel Medsystems
Channel Medsystems is a privately held company dedicated to transforming women’s healthcare globally through the development and commercialization of its flagship product, the Cerene® Cryotherapy Device. Cerene is a non-hormonal, incision-free treatment designed to provide safe, effective, and convenient therapy for women suffering from heavy menstrual bleeding (HMB) and dysmenorrhea. Offering a modern alternative to invasive surgery or long-term medications, Channel Medsystems is committed to improving patient outcomes, broadening access, and empowering women with greater control over their care.
For more information, please visit www.cerene.com.
Media Contact:
Tara Murphy
Vice President, Marketing
tmurphy@cerene.com
215-620-3004
Important Safety Information
Cerene® Cryotherapy Device is indicated to ablate the endometrial lining of the uterus in premenopausal women with heavy menstrual bleeding due to benign causes for whom childbearing is complete. Pregnancy following the Cerene procedure can be dangerous; therefore, contraception must be used until menopause. The Cerene procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. As with all surgical procedures, there are risks and considerations associated with the use of the Cerene Cryotherapy Device. Temporary side effects may include cramping, nausea, vomiting, vaginal discharge and spotting. For detailed benefit and risk information, consult the Cerene Instructions for use (IFU) or your healthcare professional. Learn More
